ISRG · Investment summary · as of 4 August 2026
Priced below what the business already delivers
Business type: Compounder · mature and structurally stable
Size is the strategy's, set against its own position and exposure limits.
At $375.43, ISRG requires a -0% five-year revenue growth rate to justify its enterprise value — less than the business already delivers, at 21%.
The disagreement with the market is about the DURABILITY OF PROCEDURE-VOLUME GROWTH, not about margin.
The value rests on an exit multiple of 52.5x, a terminal operating margin of 31% and a 9.7% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: A structural reset of robotic-surgery procedure growth from mid-to-high teens to high single digits, caused by (a) credible multi-vendor platform competition reaching commercial scale -- Medtronic's Hugo and Johnson & Johnson's Ottava are the named vehicles -- which converts ISRG's installed base from a captive annuity into a contested one, and (b) hospital capital-budget and reimbursement pressure pushing procedures toward lower-priced systems and extended-use instruments, compressing revenue per procedure.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | The disagreement with the market is about the DURABILITY OF PROCEDURE-VOLUME GROWTH, not about margin. |
| What do we forecast? | Revenue growth of 21% demonstrated; a terminal operating margin of 31%; an exit multiple of 52.5x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is +21.1 percentage points. |
| What is it worth? | Twelve-month target $439.00, +17% from the struck price. Scenario-weighted expected return net of costs +16.8%. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| 20 October 2026 | Next results (date estimated, not issuer-confirmed) | Revenue and margin in line with, or above, the house path | A miss that moves the full-year path below the guided floor |
| any two consecutive quarters from Q3-2026 | Da Vinci procedure growth, YoY, as disclosed in the quarterly… | Worldwide da Vinci procedure growth at or above 12.0% for two consecutive quarters | Worldwide da Vinci procedure growth below 12.0% for two consecutive quarters |
| any two consecutive quarters from Q3-2026 | I&A revenue YoY minus total procedure growth YoY | Instruments-and-accessories revenue growth falls no more than 3pp below worldwide procedure growth for two consecutive… | Instruments-and-accessories revenue growth falls more than 3pp below worldwide procedure growth for two consecutive… |
| any two consecutive quarters from Q3-2026 | GAAP income from operations / revenue | GAAP operating margin at or above 27.0% for two consecutive quarters | GAAP operating margin below 27.0% for two consecutive quarters |
Dates marked as estimated are drawn from the company’s own reporting cadence, not from an announcement.
A structural reset of robotic-surgery procedure growth from mid-to-high teens to high single digits, caused by (a) credible multi-vendor platform competition reaching commercial scale -- Medtronic's Hugo and Johnson & Johnson's Ottava are the named vehicles -- which converts ISRG's installed base from a captive annuity into a contested one, and (b) hospital capital-budget and reimbursement pressure pushing procedures toward lower-priced systems and extended-use instruments, compressing revenue per procedure. The permanent element is not the multiple: it is that the instruments-and-accessories stream per installed system stops growing, which removes the compounding mechanism the COMPOUNDER archetype requires.
Estimated probability 20%. No loss magnitude is on file, so the level at which the position would be resized cannot be struck and this case cannot be monitored against a loss budget.
Falsifiable and fundamental — not one of them is a price condition.
On approach to the $439.00 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Met | Is the business worth owning under its declared economic type? |
| Valuation | Met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | A structural reset of robotic-surgery procedure growth from mid-to-high teens to high single digits, caused by (a) credible multi-vendor platform competition reaching commercial scale -- Medtronic's Hugo and Johnson & Johnson's Ottava are the named vehicles -- which converts ISRG's installed base from a captive annuity into a contested one, and (b) hospital capital-budget and reimbursement pressure pushing procedures toward lower-priced systems and extended-use instruments, compressing revenue per procedure. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Not determined | Is there a dated event that resolves the disagreement? Not established on the evidence on file. |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The strongest case for mispricing is that the business already delivers +21.1 percentage points more growth than the price requires. The most important unresolved uncertainty is the permanent-loss mechanism: a structural reset of robotic-surgery procedure growth from mid-to-high teens to high single digits, caused by (a) credible multi-vendor platform competition reaching commercial scale -- Medtronic's Hugo and Johnson & Johnson's Ottava are the named vehicles -- which converts ISRG's installed base from a captive annuity into a contested one, and (b) hospital capital-budget and reimbursement pressure pushing procedures toward lower-priced systems and extended-use instruments, compressing revenue per procedure. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $325.84, which forces an immediate review.